Asparaginase Market Insight by Growth Rate, Industry Status, Forecast till 2030 – Reports and Data

June 30 05:40 2022
Asparaginase Market Insight by Growth Rate, Industry Status, Forecast till 2030 - Reports and Data
Reports and Data | Asparaginase Market
Increasing prevalence of Acute Lymphoblastic Leukemia (ALL) is one of the major factors driving market revenue growth

The global asparaginase market size is expected to reach USD 2,619.3 Million in 2030 and register a revenue CAGR of 16.7%, according to latest report by Reports and Data. Some major factors driving market revenue growth include growing pharmaceutical and food industries, increasing population, rapid urbanization, and increasing income in several countries across the world. Moreover, market players are investing in research & development and production of asparaginase to meet regulatory specifications and increasing demand. However, side effects associated with asparaginase, such as pancreatitis, mild bone marrow suppression, increased risk of stroke and bleeding, decreased protein synthesis, and hypersensitivity or allergic reaction, can limit its adoption and thereby hamper market revenue growth.

Mergers and acquisitions between asparaginase manufacturers and finished product manufacturers, such as manufacturers of pharmaceuticals and food products, is a major trend observed in the global market. There are significant growth opportunities for companies manufacturing asparaginase in regions, such as North America, Europe, and Asia-Pacific, which can be attributed to high demand for pharmaceuticals across these regions. In addition, companies can generate opportunities through collaboration with end-users, i.e., food and pharmaceutical manufacturers. 

Some Key Highlights from the Report:

  • Based on source, the Escherichia coli segment is expected to account for a substantially large revenue share over the forecast period, as it is the most widely used form of asparaginase and prior studies have highlighted its importance in the treatment of childhood acute lymphoblastic leukemia. 
  • Based on application, the acute lymphoblastic leukemia (ALL) segment is expected to account for a significantly large revenue share throughout the forecast period. Increasing prevalence of acute lymphoblastic leukemia is expected to drive growth of this segment over the forecast period.
  • Based on the route of administration, the intravenously segment is expected to register a robust revenue CAGR during the forecast period, as it is the fastest way of administering medication. Since a drug can enter the bloodstream immediately, the effect of the drug is quick when it is administered intravenously in comparison to intramuscular administration.

Get PDF Sample for this Research Report @ https://www.reportsanddata.com/download-summary-form/4306

  • Based on age group, the pediatric segment is expected to lead in terms of revenue share over the forecast period, owing to increasing prevalence of acute lymphoblastic leukemia in pediatric patients.
  • Based on distribution channel, the hospital pharmacy segment is expected to account for largest revenue share during the forecast period, owing to increasing prescription of medications at hospitals due to frequent diagnoses at these institutes.
  • The market in North America is expected to account for largest revenue share throughout the forecast period, which can be attributed to rising prevalence of leukemia. According to the American Cancer Society estimates, there were approximately 61,090 new cases and 23,660 deaths from leukemia in the U.S. in 2021. 
  • Europe is expected to account for a significantly large revenue share between 2021 and 2030. Countries such as Germany, the U.K., and France are major revenue contributors in this region. Increasing number of patients with acute lymphocytic leukemia in Europe is expected to boost demand for asparaginase in the region. According to Cancer Research U.K., there are around 790 new acute lymphoblastic leukemia cases in the U.K. every year
  • Some major companies profiled in the market report are Jazz Pharmaceuticals (Ireland), Medac GmbH (Germany), Taj Pharmaceuticals Ltd. (India), LGM Pharma (U.S.), Actiza Pharmaceutical Pvt. Ltd. (India), Gennova Biopharmaceuticals (Emcure Pharma) (India), Kyowa Hakko Kirin Co., Ltd. (Japan), Merck (Germany), Servier Pharmaceuticals LLC (France), and Novus Biologicals LLC (U.S.). 

  • In November 2021, ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells announced the granting of U.S patent 11,141,468, covering methods of treating solid tumors by administering methioninase and asparaginase. These patent families protect ERYTECH’s proprietary red blood cell encapsulation technology (ERYCAPS), its therapeutics for Oncology, Rare Metabolic Diseases, and Immune Modulation, as well as its methods for producing Cargo-Loaded Red Cell Extracellular Vesicles (CLRCEV).
  • In August 2021, Lonza expanded its microbial capacity and extended long-term partnership with Servier Laboratories for L-asparaginase API Manufacturing. The extension and expansion of the collaboration will provide Servier Laboratories with the additional capacity required to provide treatment to many more patients with acute lymphoblastic leukemia (ALL), a cancer of the white blood cells.

For this report, Reports and Data has segmented the global asparaginase market based on source, application, route of administration, age group, distribution channel, and region:

Source Outlook (Revenue, USD Million, 2019 – 2030)

  • Erwinia Chrysanthemi
  • Escherichia Coli

Application Outlook (Revenue, USD Million, 2019 – 2030)

  • Acute Lymphoblastic Leukemia (ALL)
  • Lymphoblastic Lymphoma (LBL)

Route of Administration Outlook (Revenue, USD Million, 2019 – 2030)

  • Intramuscularly
  • Intravenously

Age Group Outlook (Revenue, USD Million, 2019 – 2030)

  • Pediatric
  • Adult

Distribution Channel Outlook (Revenue, USD Million, 2019 – 2030)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Regional Outlook (Revenue, USD Million, 2019 – 2030)

  • North America
    • S.
    • Canada
  • Europe
    • Germany
    • K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Africa
    • Rest of MEA

Request For Custom Research @ https://www.reportsanddata.com/request-customization-form/4306

Media Contact
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Phone: +1-212-710-1370
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States
Website: https://www.reportsanddata.com/report-detail/asparaginase-market